Combination therapy shows significant reduction in risk of recurrence and metastasis
- Moderna’s stock rallies 7.9% after positive trial data
- Combination of Moderna’s mRNA-4157 and Merck’s Keytruda shows promising results in melanoma treatment
- Risk of recurrence or death reduced by 49% with combination therapy
- Risk of distant metastasis or death reduced by 62% with combination therapy
- Phase 3 trials of mRNA-4157 and Keytruda already underway
Moderna Inc.’s stock jumped 7% after announcing positive data from a mid-stage trial of their melanoma treatment, mRNA-4157, in combination with Merck’s Keytruda. The trial showed a 49% reduction in the risk of recurrence or death and a 62% reduction in the risk of distant metastasis or death compared to Keytruda alone. Phase 3 trials of the combination therapy are already underway, signaling further potential for Moderna’s stock.
Factuality Level: 8
Factuality Justification: The article provides specific information about the positive data from a mid-stage trial of Moderna’s mRNA-4157 in combination with Merck’s Keytruda in patients with melanoma. It includes quotes from a senior VP at Moderna and mentions that Phase 3 trials have already started. The article also provides stock performance information for Moderna and the S&P 500.
Noise Level: 8
Noise Justification: The article provides information about Moderna’s stock performance and positive data from a mid-stage trial of their drug in combination with Merck’s Keytruda. However, it lacks scientific rigor and intellectual honesty as it does not provide any details about the trial, such as sample size, methodology, or statistical significance. It also does not provide any evidence or data to support the claims made about the reduction in risk of recurrence or death. Additionally, the article includes irrelevant information about Moderna’s stock performance and the performance of the S&P 500, which is not directly related to the trial results.
Financial Relevance: Yes
Financial Markets Impacted: Moderna Inc.’s stock
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to financial topics as it discusses the positive data from a mid-stage trial of Moderna’s mRNA-4157 and its impact on the company’s stock.
Public Companies: Moderna Inc. (MRNA), Merck (MRK)
Key People: Dr. Kyle Holen (Senior VP and Head of Development, Therapeutics and Oncology at Moderna)
Reported publicly:
www.marketwatch.com 
